Organ Preservation Solutions Market Size, Share, Growth and Forecast (2026 - 2036)

Organ Preservation Solutions Market Forecast and Outlook By Fact.MR

• In 2025, the organ preservation solutions market was valued at USD 286.3 million.
• Based on Fact.MR analysis, demand for organ preservation solutions is estimated to grow to USD 309.2 million in 2026 and USD 655.0 million by 2036.
• FACT.MR projects a CAGR of 7.8% during the forecast period.
• Between 2026 and 2036, the market is projected to generate USD 345.8 million in absolute opportunity.
• Growth reflects accelerating transplant infrastructure investment and increasing organ discard reduction mandates.
• Expansion is constrained by limited donor organ supply, high machine perfusion device costs, and reimbursement gaps in developing transplant systems.

Summary of organ preservation solutions market

• Market Definition
  • The market covers chemical preservation formulations and perfusion solutions used to maintain donor organ viability during procurement, storage, and transport for kidney, liver, lung, and heart transplantation globally.
• Demand Drivers
  • U.S. transplant centers are adopting hypothermic machine perfusion under UNOS organ utilization improvement initiatives, increasing per-procedure solution volumes for marginal donor organs.
  • China's national organ donation reform program is expanding transplant center infrastructure, driving institutional procurement of preservation solutions across newly accredited facilities.
  • India's government transplant awareness and hospital expansion programs are creating new institutional buyer segments for cold storage and machine perfusion solutions in tier 2 cities.
• Key Segments Analyzed
  • By Technique: Static cold storage holds approximately 50% share in 2026, driven by cost efficiency and universal clinical acceptance across all transplant settings globally.
  • By Organ Type: Kidneys account for approximately 48% of demand in 2026, reflecting the highest global transplant procedure volumes among all solid organ categories.
  • By Solution Type: University of Wisconsin solution leads with approximately 45% share in 2026, supported by broad clinical validation and gold-standard status across kidney and liver transplantation.
  • By Application: Organ transplantation represents approximately 75% of demand in 2026, as institutional preservation protocols are defined by transplant procedure volumes.
  • By End User: Organ transplant centers hold approximately 55% share in 2026, driven by concentrated surgical volume and direct procurement relationships with solution suppliers.
  • By Geography: China leads at 9.5% CAGR through 2036, underpinned by transplant infrastructure reform and expanding organ donation registries.
• Analyst Opinion at FACT.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, opines, ' CXOs will notice that the real shift in value is coming from machine perfusion adoption. Transplant centers are focusing less on the low cost of static cold storage. Instead, they are prioritizing better organ utilization. Machine perfusion allows more organs to be used, including those from marginal donors. This directly improves transplant success rates and reduces discard levels.
• Strategic Implications
  • Invest in normothermic and hypothermic machine perfusion solution portfolios with documented organ viability outcome data to capture procurement contracts at high-volume transplant centers.
  • Develop cost-optimised University of Wisconsin and HTK solution formats for emerging transplant markets in India and China, where government program procurement prioritises clinical efficacy at competitive pricing.
  • Establish supply partnerships with organ procurement organizations in the United States and Europe to secure recurring solution volume within GPO and network procurement frameworks.
• Methodology
  • Market sizing uses transplant procedure volumes and per-procedure solution spend, validated against UNOS, Eurotransplant, and HRSA registry data from 2024 to 2025.
  • Analysis incorporates FDA 510(k) records, national transplant authority reports, and company revenue disclosures from XVIVO Perfusion, TransMedics, and OrganOx.
  • Forecasts account for machine perfusion adoption trajectories, marginal donor utilization policy trends, and organ procurement organization procurement benchmarks by country.

China leads with an estimated CAGR of 9.5% through 2036, underpinned by transplant infrastructure reform and rapidly expanding organ donation registries. India follows at 9.0%, driven by government-funded transplant awareness programs and hospital network expansion. The United States records 8.2%, where machine perfusion adoption and marginal donor organ utilization protocols sustain steady procurement growth. Japan records 7.4%, shaped by aging demographics and growing organ failure incidence. Germany grows at 7.1%, supported by advanced transplant center infrastructure and strong regulatory frameworks. Brazil records 6.8%, driven by expanding private ophthalmic and transplant surgical infrastructure.

Segmental Analysis

Organ Preservation Solutions Market Analysis by Technique

Based on FACT.MR's organ preservation solutions market report, static cold storage holds approximately 50% share in 2026. It leads due to low cost, procedural simplicity, and universal clinical acceptance across all transplant settings globally.

• XVIVO Machine Perfusion Expansion: XVIVO Perfusion AB expanded its XPS lung perfusion platform distribution to 14 additional transplant centers in the United States and Europe in 2024. The company disclosed increasing per-center solution volume as centers adopted normothermic perfusion for extended criteria donor lungs. [4]
• OrganOx metra Commercial Rollout: OrganOx Limited reported expanded commercial placements of its metra normothermic liver perfusion device in the United Kingdom, Germany, and Australia during 2024. Each device placement is accompanied by recurring normothermic perfusion solution procurement. [5]
• Static Cold Storage Persistence in Emerging Markets: HRSA organ procurement data from 2024 confirms that static cold storage remains the dominant technique in transplant facilities outside major academic centers in the United States. [6]

Organ Preservation Solutions Market Analysis by Organ Type

Based on FACT.MR's report, kidneys account for approximately 48% of organ preservation solution demand in 2026. Kidney transplant volumes are the highest of any solid organ globally, creating the largest procedural base for solution consumption.

• Kidney Transplant Volume Growth: UNOS data released in 2024 reported that U.S. kidney transplant volumes reached record levels in fiscal year 2023, driven by expanded deceased donor utilization and living donor program growth. [7]
• Liver Perfusion Technology Adoption: TransMedics Group reported record Organ Care System liver utilization in its 2024 annual results, with normothermic liver perfusion solution volumes increasing year-on-year as centers adopted the platform for extended criteria donor livers. [8]
• Heart Preservation Solution Innovation: Paragonix Technologies received FDA clearance for the SherpaPak cardiac transport system update in 2024, targeting improved static cold storage outcomes for heart transplantation. [9]

Organ Preservation Solutions Market Analysis by Preservation Solution Type

Based on FACT.MR's report, University of Wisconsin solution holds approximately 45% share in 2026. Its leadership reflects gold-standard clinical status for kidney and liver preservation, backed by decades of outcome validation.

• Preservation Solutions Inc. UW Solution Supply: Preservation Solutions Inc. retained its position as the primary UW solution supplier to U.S. organ procurement organizations through long-term supply agreements. [10]
• Dr. Franz Köhler HTK Solution Distribution: Dr. Franz Köhler Chemie expanded Custodiol HTK solution distribution through new distributor agreements in Southeast Asia and the Middle East in 2025. The company disclosed distribution partnerships in Singapore, Malaysia, and the UAE targeting newly accredited transplant centers.
• BioLife Solutions Cryopreservation Integration: BioLife Solutions Inc. reported expansion of its HypoThermosol and CryoStor solution portfolio into transplant-adjacent research and cell therapy applications in 2024.

Organ Preservation Solutions Market Analysis by Application

Based on FACT.MR's report, organ transplantation accounts for approximately 75% of preservation solution demand in 2026. Transplantation is the procedurally mandated application where solution use is non-discretionary at every donor organ procurement.

• Transplant Volume-Driven Procurement: Eurotransplant's 2024 annual report disclosed that kidney, liver, lung, and heart transplant volumes across its eight-country network increased year-on-year. Each additional transplant procedure requires organ procurement solution at the donor hospital and preservation solution at the receiving transplant center.
• Ex Vivo Research Program Expansion: Academic medical centers in the United States, United Kingdom, and Germany expanded ex vivo organ perfusion research programs in 2024 and 2025.
• Emerging Market Transplant Program Growth: India's Transplantation of Human Organs and Tissues Authority reported a 28% increase in deceased donor transplant activity in fiscal year 2023-24.

Organ Preservation Solutions Market Analysis by End User

Based on FACT.MR's report, organ transplant centers account for approximately 55% of preservation solution demand in 2026. Transplant centers drive the largest share because they manage both organ receipt and implantation, requiring solution at multiple procedural steps. Hospitals with in-house transplant units represent a secondary procurement channel.

• Transplant Center Procurement Consolidation: Major U.S. academic transplant centers including those affiliated with large health systems are consolidating preservation solution procurement through system-level contracts.
• Hospital Channel Growth in Asia: In China, the National Health Commission's 2024 accreditation expansion added 38 transplant-approved hospital facilities. These hospitals procure preservation solutions independently through regional medical device distributor channels rather than through centralized OPO frameworks.
• Specialty Clinic Segment Emergence: In Europe, specialty kidney transplant clinics operating independently of large academic centers are expanding in Germany, Spain, and the Netherlands. These facilities procure cold storage solutions directly from distributors under national transplant authority-approved procurement guidelines.

Drivers, Restraints, and Opportunities

FACT.MR analysts observe the organ preservation solutions market is clinically established but undergoing significant technique disruption. Demand is anchored in kidney and liver transplantation, where solution use is procedurally mandated.

Static cold storage solutions are stable in volume but declining as a proportion of per-procedure spend as machine perfusion adoption grows. Hypothermic and normothermic machine perfusion solutions command significantly higher per-procedure spend than static cold storage fluids.

• UNOS Organ Utilization Improvement: The United Network for Organ Sharing updated its organ utilization improvement framework in 2024, introducing accountability metrics for transplant centers that decline marginal-quality kidneys and livers. This policy creates institutional incentive to adopt machine perfusion technology that supports marginal organ acceptance. [1]
• China Transplant Infrastructure Reform: China's National Health Commission expanded its transplant center accreditation programme in 2024, adding 38 new approved transplant facilities. Each accredited center is required to maintain organ preservation solution procurement under defined clinical guidelines. [2]
• EU Organ Directive and Machine Perfusion Standards: The European Commission's updated Organ Directive implementation guidance, issued in 2025, reinforced machine perfusion as a recommended technique for extended criteria donor organs across EU member states. Germany and France incorporated the guidance into national transplant authority procurement frameworks. [3]

Regional Analysis

The organ preservation solutions market is assessed across Asia Pacific, North America, Europe, Latin America, and Middle East and Africa, covering 40+ countries with demand shaped by transplant procedure volumes, organ donation registry maturity, machine perfusion adoption rates, and national transplant authority accreditation frameworks. The full report offers market attractiveness analysis by region and country.

Source: Fact.MR (FACT.MR) analysis, based on proprietary forecasting model and primary research

Asia Pacific Organ Preservation Solutions Market Analysis

Asia Pacific is the fastest-growing region, driven by transplant infrastructure reform in China and government-funded program expansion in India. Japan maintains high preservation solution quality standards aligned with advanced surgical adoption.

• China: Rapid expansion of transplant infrastructure is driving demand, with growth projected at 9.5% CAGR through 2036. Newly accredited centers are increasing procurement volumes. National allocation reforms are standardizing preservation protocols. Tier-2 hospitals are becoming active transplant hubs. Bridge to Life Ltd. and Dr. Franz Köhler Chemie GmbH are strengthening distribution networks. Demand is rising for UW and HTK solutions. Growth is policy-led and infrastructure-driven.
• India: Rising transplant activity is accelerating demand, with growth at 9.0% CAGR through 2036. Deceased donor programs are expanding across key states. Hospital certification is increasing the number of eligible transplant centers. Procurement is regulated through national guidelines. Preservation Solutions Inc. and Bridge to Life Ltd. supply through import channels. Demand is growing alongside institutional capacity.

FACT.MR covers China, India, Japan, South Korea, ASEAN, and Australia. Readers can find transplant volume trends, preservation protocol adoption patterns, and regulatory-driven procurement insights across Asia Pacific markets.

North America Organ Preservation Solutions Market Analysis

North America leads in value and technology adoption. Machine perfusion is widely integrated into transplant workflows. Procurement is structured through national allocation systems and hospital networks.

• United States: Policy-driven utilization improvements are shaping demand, with growth at 8.2% CAGR through 2036. Transplant centers are incentivized to use marginal donor organs. Machine perfusion is increasing per-procedure spend. TransMedics Group Inc. is expanding Organ Care System usage. XVIVO Perfusion AB is strengthening transplant center relationships. Growth is driven by outcomes and utilization efficiency.

FACT.MR covers the United States, Canada, and Mexico. Readers can find organ utilization trends, machine perfusion adoption rates, and transplant center procurement frameworks across North America.

Europe Organ Preservation Solutions Market Analysis

Europe operates under coordinated transplant frameworks. Standardized protocols influence procurement decisions. Advanced clinical practices support technology adoption.

• Germany: Structured allocation systems are sustaining demand, with growth at 7.1% CAGR through 2036. Eurotransplant protocols are guiding preservation practices. Clinical guidelines are encouraging machine perfusion use. Dr. Franz Köhler Chemie GmbH supplies HTK solutions through established contracts. OrganOx Limited is expanding perfusion system adoption. Growth is compliance-driven and steady.
• Japan: Demographic pressure is increasing transplant demand, with growth at 7.4% CAGR through 2036. Aging population is expanding waiting lists. National guidelines are standardizing solution usage. HOKA Medical supports supply through local channels. Academic centers are adopting machine perfusion technologies. Growth is gradual and clinically driven.

Latin America Organ Preservation Solutions Market Analysis

Latin America is developing through public system expansion and private sector investment. Demand is split between government-funded programs and private hospital adoption.

• Brazil: Public transplant programs are driving baseline demand, with growth at 6.8% CAGR through 2036. National coordination ensures structured procurement. Clinical guidelines specify approved solution types. Private hospitals are adopting advanced perfusion technologies. Bridge to Life Ltd. and Preservation Solutions Inc. supply through import networks. Growth reflects both public volume and private innovation.

FACT.MR covers Brazil, Argentina, Mexico, Colombia, Chile, and Rest of Latin America. Readers can find transplant trends, procurement frameworks, and technology adoption insights.

Competitive Aligners for Market Players

The organ preservation solutions market is not fully consolidated, but the competitive lines are becoming clearer. Traditional preservation solutions still hold a strong base, especially in static cold storage. At the same time, competition is intensifying around machine perfusion platforms, where most of the value is shifting.

Companies like XVIVO Perfusion AB, TransMedics Group Inc., and OrganOx Limited are leading in the high-value segment. Their strength comes from combining devices with proprietary solutions. This creates a recurring revenue stream every time their systems are used. In contrast, players such as Preservation Solutions Inc., Dr. Franz Köhler Chemie GmbH, and Bridge to Life Ltd. remain strong in traditional cold storage through long-standing supply agreements with hospitals and organ procurement organizations.

The biggest shift is how solutions are bundled. Platform-based companies are not just selling a product. They are offering a complete system that includes the device, the solution, and ongoing support. This makes it harder for standalone solution providers to compete, especially on value.

Companies like Getinge AB and BioLife Solutions Inc. are positioning themselves differently. They focus on logistics, storage infrastructure, and adjacent biopreservation areas rather than direct competition in core perfusion systems.

Procurement behavior is also changing. Large transplant centers prefer integrated agreements with fewer vendors. This simplifies operations and ensures consistency. As a result, companies offering full-platform solutions are gaining an edge, while standalone suppliers are increasingly competing on price.

Key Players

• XVIVO Perfusion AB
• TransMedics Group Inc.
• OrganOx Limited
• Paragonix Technologies
• Getinge AB
• BioLife Solutions Inc.
• Bridge to Life Ltd.
• Dr. Franz Köhler Chemie GmbH
• Preservation Solutions Inc.

Bibliography

• [1] United Network for Organ Sharing (UNOS). Organ Utilization Improvement Initiative 2024: updated performance accountability metrics for transplant centers on marginal donor organ acceptance and machine perfusion adoption; 2024. Available from: unos.org/transplant/policies
• [2] National Health Commission of China. Transplant Center Accreditation Expansion 2024: approval of 38 new transplant facilities and updated organ preservation solution procurement requirements under national clinical guidelines; 2024. Available from: nhc.gov.cn
• [3] European Commission. Updated Organ Directive Implementation Guidance 2025: machine perfusion recommendations for extended criteria donor organs and member state transplant authority procurement framework integration; January 2025. Available from: ec.europa.eu/health/organ-donation
• [4] XVIVO Perfusion AB. Annual Report 2024: XPS lung perfusion platform distribution expansion to 14 additional transplant centers in the United States and Europe with associated perfusion solution volume growth; 2024. Available from: xvivoperfusion.com/investors
• [5] OrganOx Limited. Investor Communications 2024: metra normothermic liver perfusion device commercial placements in the United Kingdom, Germany, and Australia with institutional NHS and private hospital supply agreements; 2024. Available from: organox.com
• [6] Health Resources and Services Administration (HRSA). Organ Procurement and Transplantation Network Data 2024: deceased donor organ procurement volumes by technique and organ type including static cold storage dominance in non-academic transplant settings; 2024. Available from: hrsa.gov/organ-donation
• [7] United Network for Organ Sharing (UNOS). Annual Data Report 2024: record kidney transplant volumes in fiscal year 2023 driven by expanded deceased donor utilization and living donor program growth; 2024. Available from: unos.org/data
• [8] TransMedics Group Inc. Annual Report 2024: record Organ Care System liver utilization and normothermic perfusion solution volume growth at contracted U.S. and European transplant centers; 2024. Available from: transmedics.com/investors
• [9] Paragonix Technologies. FDA Clearance Announcement 2024: updated 510(k) clearance for SherpaPak cardiac transport system with integrated proprietary preservation solution for extended cardiac cold storage; 2024. Available from: paragonix.com/news
• [10] Preservation Solutions Inc. Supply Agreement Disclosures 2024: continued OPO supply contract renewals for University of Wisconsin preservation solution across major U.S. organ procurement organizations; 2024. Available from: preservationsolutions.com

This Report Addresses

• Strategic demand intelligence across China, India, the United States, Japan, Germany, and Brazil, covering transplant volume trends and machine perfusion solution adoption trajectories by country.
• Market forecast from USD 309.2 million in 2026 to USD 655.0 million by 2036, at 7.8% CAGR, with absolute dollar opportunity of USD 345.8 million.
• Opportunity mapping across China transplant infrastructure accreditation, India NOTTO certification expansion, U.S. UNOS organ utilization policy, and EU Organ Directive machine perfusion guidance.
• Segment forecasts by technique, organ type, solution type, application, and end user, covering static cold storage, machine perfusion, UW solution, kidney and liver applications, and transplant center procurement channels.
• Competitive analysis of XVIVO Perfusion, TransMedics Group, OrganOx, Paragonix Technologies, Getinge, BioLife Solutions, Bridge to Life, Dr. Franz Köhler Chemie, and Preservation Solutions Inc.
• Technology tracking on normothermic machine perfusion adoption, HTK and UW solution clinical positioning, and machine perfusion platform-solution integration strategies at transplant centers.
• Regulatory impact analysis covering UNOS organ utilization frameworks, EU Organ Directive implementation guidance, HRSA organ procurement data, and national transplant authority accreditation requirements.
• Report delivery in PDF, Excel, and presentation formats with validated data from transplant registries, regulatory filings, and primary interviews with transplant surgery and procurement specialists.

Organ Preservation Solutions Market Definition

The organ preservation solutions market covers the chemical formulations and perfusion systems used to maintain viability of donor organs from procurement through transplantation. These solutions prevent cellular deterioration during cold or normothermic storage.

Organ Preservation Solutions Market Inclusions

Covers global and regional forecasts from 2026 to 2036 by technique, organ type, solution type, application, and end user. Includes static cold storage solutions, hypothermic machine perfusion fluids, and normothermic perfusion solutions.

Organ Preservation Solutions Market Exclusions

Excludes perfusion devices and machine hardware as standalone capital equipment. Omits surgical consumables, immunosuppressants, and organ transport containers unless solution-integrated.

Organ Preservation Solutions Market Research Methodology

• Primary Research
  • Interviews with transplant surgeons, organ procurement organization coordinators, hospital procurement managers, and perfusion technology specialists across key transplant markets.
• Desk Research
  • Uses UNOS and Eurotransplant registry data, HRSA organ procurement reports, FDA 510(k) and PMA records, company annual reports, and national transplant authority disclosures from 2024 to 2025.
• Market-Sizing and Forecasting
  • Applies a hybrid model using transplant procedure volumes by organ type, average solution spend per procedure, and machine perfusion adoption rates by country income group.
• Data Validation and Update Cycle
  • Validated against transplant registry volumes and manufacturer revenue disclosures. Cross-checked with organ procurement organization procurement data. Updated on a regular cycle using regulatory and clinical databases.